Noninvasive Submental Fat Compartment Treatment

BACKGROUND: KYBELLA, ATX-101, is an injectable form of sodium deoxycholic acid. It is currently the only Food and Drug Administration–approved injectable drug for the reduction of submental fat. OBJECTIVES: A literature review and discussion of the treatment of submental fat. RESULTS: KYBELLA is a w...

Descripción completa

Detalles Bibliográficos
Autor principal: Shamban, Ava T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
Meeting Proceedings Cosmetic Bootcamp
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172481/
https://www.ncbi.nlm.nih.gov/pubmed/28018773
http://dx.doi.org/10.1097/GOX.0000000000001155
Descripción
Sumario:BACKGROUND: KYBELLA, ATX-101, is an injectable form of sodium deoxycholic acid. It is currently the only Food and Drug Administration–approved injectable drug for the reduction of submental fat. OBJECTIVES: A literature review and discussion of the treatment of submental fat. RESULTS: KYBELLA is a well-tolerated alternative for the treatment of submental fat. CONCLUSIONS: KYBELLA is a safe and efficacious, first in class, injectable drug for the reduction of submental fat.

Ejemplares similares